Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LIPELLA PHARMACEUTICALS INC.LIPO · Entity 8772 | Director | June 16, 2023 | June 21, 2023 |
| PAVmed Inc.PAVM · Entity 7317 | Director | April 01, 2021 | April 05, 2021 |
| Scopus BioPharma Inc.SCPS · Entity 133074 | Director | December 16, 2020 | December 28, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LIPELLA PHARMACEUTICALS INC.
Report date June 16, 2023 · Filed June 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.19 · Expires 2033-06-16 | Direct | 25,000 |
Reported balance
After 2023-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-16 · Grant · Acquired 25,000 · Balance 25,000 |
PAVmed Inc.
Report date April 01, 2021 · Filed April 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.44 · Expires 2031-04-01 | Direct | 50,000 |
Reported balance
After 2021-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-01 · Grant · Acquired 50,000 · Balance 50,000 F1: The option vests in 12 equal quarterly installments commencing on September 30, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in 12 equal quarterly installments commencing on September 30, 2021.
Scopus BioPharma Inc.
Report date December 16, 2020 · Filed December 28, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2025-12-15 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-12-16 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2023 Filed Jun 21, 2023 21:00 UTC | LIPELLA PHARMACEUTICALS INC. LIPO · Entity 8772 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001753926-23-000833 · ownership.xml · derivative · entry 1 Battleman David S. · CIK 0001714335 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-16 Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 23:09 UTC | PAVmed Inc. PAVM · Entity 7317 | GrantEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001094891-21-000180 · edgar.xml · derivative · entry 1 Battleman David S. · CIK 0001714335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-04-01 F1 · derivative.exercise_date: The option vests in 12 equal quarterly installments commencing on September 30, 2021. Read SEC document |
| April 30, 2020 Filed May 4, 2020 21:45 UTC | PAVmed Inc. PAVM · Entity 7317 | GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001094891-20-000068 · edgar.xml · derivative · entry 1 Battleman David S. · CIK 0001714335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-04-30 F1 · derivative.exercise_date: The option vests in 12 equal quarterly installments commencing on June 30, 2020. Read SEC document |
| March 07, 2019 Filed Mar 12, 2019 11:59 UTC | PAVmed Inc. PAVM · Entity 7317 | GrantEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001094891-19-000088 · edgar.xml · derivative · entry 1 Battleman David S. · CIK 0001714335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-03-07 F1 · derivative.exercise_date: The option vests in 12 equal quarterly installments commencing on March 31, 2019. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 21:27 UTC | PAVmed Inc. PAVM · Entity 7317 | GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001094891-18-000051 · edgar.xml · derivative · entry 1 Battleman David S. · CIK 0001714335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-02-14 F1 · derivative.exercise_date: The option vests in 12 equal quarterly installments commencing on March 31, 2018. Read SEC document |
| August 03, 2017 Filed Aug 11, 2017 14:38 UTC | PAVmed Inc. PAVM · Entity 7317 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0001094891-17-000172 · edgar.xml · derivative · entry 1 Battleman David S. · CIK 0001714335 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-08-02 F1 · derivative.exercise_date: The option shall become exercisable as to one-twelfth (1/12) of the option shares on September 30, 2017, and shall become exercisable as to one-twelfth (1/12) of the option shares on the last day of each successive fiscal quarter for the following eleven (11) fiscal quarters. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.